Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910240 | 0.73 | KCNH2 (0.41) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL15850839 | 0.73 | KCNH2 (0.41) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL15850843 | 0.73 | KCNH2 (0.41) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL910339 | 0.70 | KCNH2 (0.35) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL140992 | 0.68 | STAT3 (0.46) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL20383548 | 0.68 | ALDH1A1 (0.41) | ALDH1A1HTTPOLBCYP2D6 | |
| SCHEMBL4921650 | 0.67 | STAT3 (0.41) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL4921663 | 0.67 | STAT3 (0.41) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL4929727 | 0.67 | STAT3 (0.41) | CYP2C19ALDH1A1CYP2D6 | |
| SCHEMBL3243145 | 0.66 | ALDH1A1 (0.41) | ALDH1A1HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NRDC, NCL, NPM1 | CYP2C19 1875/4885ALDH1A1 4501/4885HTT 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.